Attorney Docket No.:

ISIS-5315 (ISIS No ISIS-2960US.P2)

Serial No.:

10/698,689

Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

1-16. (Canceled)

- 17. (Currently amended) A method of inhibiting the expression of CD40 in a cell or tissue comprising contacting said cell or tissue with an antisense compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound inhibits the expression of CD40 mRNA by at least 10% the antisense compound of claim 1-so that expression of CD40 is inhibited.
- (Original) The method of claim 17 wherein said cells are B-cells or macrophages.

19-22. (Canceled)

- 23. (Currently amended) A method of treating an animal having a disease or condition associated with CD40 comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound inhibits the expression of CD40 mRNA by at least 10% the antisense compound of claim 1 so that expression of CD40 is inhibited.
- 24. (Original) The method of claim 23 wherein the disease or condition is an immune-associated disorder, an inflammatory condition or a hyperproliferative condition.

Attorney Docket No.:

ISIS-5315 (ISIS No ISIS-2960US.P2)

Serial No.:

10/698,689

Page 3

- 25. (Original) The method of claim 24 wherein the immune-associated disorder is graft-versus-host disease, allograft rejection or an autoimmune disease or condition.
- 26. (Original) The method of claim 24 wherein the inflammatory condition is asthma, rheumatoid arthritis, allograft rejection, inflammatory bowel disease or psoriasis.
- 27. (Original) The method of claim 24 wherein the hyperproliferative condition is atherosclerosis, cancer or a tumor.

28-61. (Canceled)

- 62. (Currently amended) A method of redirecting splicing of CD40 RNA in a cell or tissue comprising contacting said cell or tissue with an antisense compound of 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound does not elict RNase H cleavage of its RNA target in an antisense compound-target RNA duplex elaim 57, so that the ratio of CD40 splice products is altered.
- 63. (Original) The method of claim 62 wherein the ratio of CD40 Type 2 transcript is increased relative to the CD40 Type 1 transcript.
- 64. (Original) The method of claim 63 wherein CD40 signaling is reduced.
- 65. (Original) The method of claim 64 wherein IL-12 cytokine production is reduced.

2005/007

Attorney Docket No.:

ISIS-5315 (ISIS No ISIS-2960US.P2)

Serial No.:

10/698,689

Page 4

- 66. (Original) A method of reducing CD40 signaling in a cell or tissue comprising contacting said cell or tissue with an antisense compound of 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound does not elict RNase H cleavage of its RNA target in an antisense compound-target RNA duplex elaim 57, so that the ratio of CD40 splice products is altered and CD40 signaling is reduced.
- 67. (Currently amended) A method of reducing IL-12 cytokine production in a cell or tissue comprising contacting said cell or tissue with an antisense compound of 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound does not elict RNase H cleavage of its RNA target in an antisense compound-target RNA duplex claim 57, so that the ratio of CD40 splice products is altered and IL-12 cytokine production is reduced.

68-69. (Canceled)